These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 21982529)

  • 1. Primary prophylaxis of cryptococcal disease with fluconazole in HIV-positive Ugandan adults: a double-blind, randomised, placebo-controlled trial.
    Parkes-Ratanshi R; Wakeham K; Levin J; Namusoke D; Whitworth J; Coutinho A; Mugisha NK; Grosskurth H; Kamali A; Lalloo DG;
    Lancet Infect Dis; 2011 Dec; 11(12):933-41. PubMed ID: 21982529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary antifungal prophylaxis for cryptococcal disease in HIV-positive people.
    Awotiwon AA; Johnson S; Rutherford GW; Meintjes G; Eshun-Wilson I
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD004773. PubMed ID: 30156270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reflexive Laboratory-Based Cryptococcal Antigen Screening and Preemptive Fluconazole Therapy for Cryptococcal Antigenemia in HIV-Infected Individuals With CD4 <100 Cells/µL: A Stepped-Wedge, Cluster-Randomized Trial.
    Meya DB; Kiragga AN; Nalintya E; Morawski BM; Rajasingham R; Park BJ; Mubiru A; Kaplan JE; Manabe YC; Boulware DR
    J Acquir Immune Defic Syndr; 2019 Feb; 80(2):182-189. PubMed ID: 30399034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cryptococcal antigenemia is associated with meningitis or death in HIV-infected adults with CD4 100-200 cells/mm
    Wykowski J; Galagan SR; Govere S; Wallis CL; Moosa MY; Celum C; Drain PK
    BMC Infect Dis; 2020 Jan; 20(1):61. PubMed ID: 31959112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antifungal interventions for the primary prevention of cryptococcal disease in adults with HIV.
    Chang LW; Phipps WT; Kennedy GE; Rutherford GW
    Cochrane Database Syst Rev; 2005 Jul; (3):CD004773. PubMed ID: 16034947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost-effectiveness of prophylaxis strategies for individuals with advanced HIV starting treatment in Africa.
    Walker SM; Cox E; Revill P; Musiime V; Bwakura-Dangarembizi M; Mallewa J; Cheruiyot P; Maitland K; Ford N; Gibb DM; Walker AS; Soares M;
    J Int AIDS Soc; 2020 Mar; 23(3):e25469. PubMed ID: 32219991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and mortality of cryptococcal disease in adults with advanced HIV in an urban tertiary hospital in Sierra Leone: a prospective study.
    Lakoh S; Rickman H; Sesay M; Kenneh S; Burke R; Baldeh M; Jiba DF; Tejan YS; Boyle S; Koroma C; Deen GF; Beynon F
    BMC Infect Dis; 2020 Feb; 20(1):141. PubMed ID: 32059703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Six-month outcomes of HIV-infected patients given short-course fluconazole therapy for asymptomatic cryptococcal antigenemia.
    Kapoor SW; Magambo KA; Kalluvya SE; Fitzgerald DW; Peck RN; Downs JA
    AIDS; 2015 Nov; 29(18):2473-8. PubMed ID: 26372487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings.
    Meya DB; Manabe YC; Castelnuovo B; Cook BA; Elbireer AM; Kambugu A; Kamya MR; Bohjanen PR; Boulware DR
    Clin Infect Dis; 2010 Aug; 51(4):448-55. PubMed ID: 20597693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial.
    Ndiaye BP; Thienemann F; Ota M; Landry BS; Camara M; Dièye S; Dieye TN; Esmail H; Goliath R; Huygen K; January V; Ndiaye I; Oni T; Raine M; Romano M; Satti I; Sutton S; Thiam A; Wilkinson KA; Mboup S; Wilkinson RJ; McShane H;
    Lancet Respir Med; 2015 Mar; 3(3):190-200. PubMed ID: 25726088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of primary prophylaxis of AIDS associated cryptococcosis in Cambodia.
    Micol R; Tajahmady A; Lortholary O; Balkan S; Quillet C; Dousset JP; Chanroeun H; Madec Y; Fontanet A; Yazdanpanah Y
    PLoS One; 2010 Nov; 5(11):e13856. PubMed ID: 21085478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefits of enhanced infection prophylaxis at antiretroviral therapy initiation by cryptococcal antigen status.
    Pett SL; Spyer M; Haddow LJ; Nhema R; Benjamin LA; Najjuka G; Bilima S; Daud I; Musoro G; Kitabalwa J; Selemani G; Kandie S; Cornelius KM; Katemba C; Berkley JA; Hassan AS; Kityo C; Hakim J; Heyderman RS; Gibb DM; Walker AS;
    AIDS; 2021 Mar; 35(4):585-594. PubMed ID: 33306556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjunctive sertraline for HIV-associated cryptococcal meningitis: a randomised, placebo-controlled, double-blind phase 3 trial.
    Rhein J; Huppler Hullsiek K; Tugume L; Nuwagira E; Mpoza E; Evans EE; Kiggundu R; Pastick KA; Ssebambulidde K; Akampurira A; Williams DA; Bangdiwala AS; Abassi M; Musubire AK; Nicol MR; Muzoora C; Meya DB; Boulware DR;
    Lancet Infect Dis; 2019 Aug; 19(8):843-851. PubMed ID: 31345462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary Prophylaxis for Cryptococcosis With Fluconazole in Human Immunodeficiency Virus-Infected Patients With CD4 T-Cell Counts <100 Cells/µL and Receiving Antiretroviral Therapy.
    Sungkanuparph S; Savetamornkul C; Pattanapongpaiboon W
    Clin Infect Dis; 2017 Apr; 64(7):967-970. PubMed ID: 28362939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Laboratory-Reflex Cryptococcal Antigen Screening Is Associated With a Survival Benefit in Tanzania.
    Faini D; Kalinjuma AV; Katende A; Mbwaji G; Mnzava D; Nyuri A; Glass TR; Furrer H; Hatz C; Boulware DR; Letang E
    J Acquir Immune Defic Syndr; 2019 Feb; 80(2):205-213. PubMed ID: 30422904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a national cryptococcal antigen screening program for HIV-infected patients in Uganda: A cost-effectiveness modeling analysis.
    Rajasingham R; Meya DB; Greene GS; Jordan A; Nakawuka M; Chiller TM; Boulware DR; Larson BA
    PLoS One; 2019; 14(1):e0210105. PubMed ID: 30629619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi.
    Nussbaum JC; Jackson A; Namarika D; Phulusa J; Kenala J; Kanyemba C; Jarvis JN; Jaffar S; Hosseinipour MC; Kamwendo D; van der Horst CM; Harrison TS
    Clin Infect Dis; 2010 Feb; 50(3):338-44. PubMed ID: 20038244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trial.
    Mfinanga SG; Kirenga BJ; Chanda DM; Mutayoba B; Mthiyane T; Yimer G; Ezechi O; Connolly C; Kapotwe V; Muwonge C; Massaga J; Sinkala E; Kohi W; Lyantumba L; Nyakoojo G; Luwaga H; Doulla B; Mzyece J; Kapata N; Vahedi M; Mwaba P; Egwaga S; Adatu F; Pym A; Joloba M; Rustomjee R; Zumla A; Onyebujoh P
    Lancet Infect Dis; 2014 Jul; 14(7):563-71. PubMed ID: 24810491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prevalence of cryptococcal antigen (CrAg) and benefits of pre-emptive antifungal treatment among HIV-infected persons with CD4+ T-cell counts < 200 cells/μL: evidence based on a meta-analysis.
    Li Y; Huang X; Chen H; Qin Y; Hou J; Li A; Wu H; Yan X; Chen Y
    BMC Infect Dis; 2020 Jun; 20(1):410. PubMed ID: 32532212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Prospective Evaluation of a Multisite Cryptococcal Screening and Treatment Program in HIV Clinics in Uganda.
    Nalintya E; Meya DB; Lofgren S; Huppler Hullsiek K; Boulware DR; Rajasingham R
    J Acquir Immune Defic Syndr; 2018 Jun; 78(2):231-238. PubMed ID: 29509588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.